knowledge -WSS

knowledge

author：hotspot 2025-10-02 23:47:49 - browse：85

An advisory committee to the Food and Drug Administration will convene on Tuesday to evaluate the benefits of renal denervation, a one-time surgical procedure that works to reduce blood pressure. The promise — and the potential market — is enormous, but the data on how well the procedure works remains contentious.

The committee will evaluate data from two companies vying for market approval: ReCor Medical, a startup owned by Japanese company Otsuka Medical Devices, and device giant Medtronic, both of which have made surgical systems to treat hypertension.

Data from an analysis of three randomized clinical trials of ReCor Medical’s device showed a modest decrease in blood pressure after two months compared to a control group that received a placebo procedure. Medtronic’s late-stage trial showed that renal denervation reduced hypertension when measuring blood pressure in the doctor’s office, but did not show a reduction in blood pressure when patients measured it at home over 24 hours. At-home blood pressure is considered the more accurate measure, as blood pressure levels tend to artificially rise with anxiety in the clinic. Neither study presented serious safety concerns.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： The thinking behind the controversial eating disorder chatbot Tessa

hotspot

explore

WSS

AstraZeneca stays mum on Medicare drug pricing negotiations

Novo: Oral version of Ozempic leads to 15% weight loss

Medicare Advantage plans can’t deny care with AI, CMS warns

How to fix the rural physician shortage in the U.S.

Mom launches Girl Scout troop for LGBTQ youth in Texas

Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

entertainment

knowledge

explore

Alkermes shareholders re

Senate panel passes drug pricing bills, but drops one PBM reform

Apple is now the first public company to be valued at $3 trillion

AI gets buy

Jerome Adams on the need for new antivirals for Covid

The Biogen Aduhelm mess could happen again

In age of alternative facts, a scholarly course on calling out crap

U.K. agency declines to back Eli Lilly’s Mounjaro for type 2 diabetes

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

knowledge

Mom launches Girl Scout troop for LGBTQ youth in Texas

Why CTE doesn’t keep Americans from enjoying the Super Bowl

The CDC's new social media misinformation war

A public health expert passes on football's full body collisions for youths

Why CTE doesn’t keep Americans from enjoying the Super Bowl

Surgery pushed Ben Carson to fame

hotspot

Wikipedia

explore

Wikipedia